531739 logo

Gennex Laboratories Limited Stock Price

BSE:531739 Community·₹2.3b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

531739 Share Price Performance

₹9.41
-4.70 (-33.31%)
₹9.41
-4.70 (-33.31%)
Price ₹9.41

531739 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Adequate balance sheet and slightly overvalued.

2 Risks
2 Rewards

Gennex Laboratories Limited Key Details

₹1.5b

Revenue

₹1.1b

Cost of Revenue

₹431.8m

Gross Profit

₹240.4m

Other Expenses

₹191.4m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
0.79
28.39%
12.58%
39.8%
View Full Analysis

About 531739

Founded
1985
Employees
115
CEO
Arihant Baid
WebsiteView website
www.gennexlab.com

Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin for muscle relaxant; and Allopurinol, a xanthine oxidase inhibitor. It has operations in India, Algeria, Bangladesh, Barzil, Bolivia, Colombia, the Czech Republic, Egypt, El Salvador, Germany, Guatemala City, Mexico, Peru, Spain, Turkey, Thailand, the United Arab Emirates, and Vietnam. Gennex Laboratories Limited was formerly known as Prudential Pharmaceuticals Limited and changed its name to Gennex Laboratories Limited in September 2007. Gennex Laboratories Limited was incorporated in 1985 and is based in Hyderabad, India.

Recent 531739 News & Updates

Recent updates

No updates